| Schizophrenia
Cobenfy vs Geodon
Side-by-side clinical, coverage, and cost comparison for schizophrenia.Deep comparison between: Cobenfy vs Geodon with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsGeodon has a higher rate of injection site reactions vs Cobenfy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Geodon but not Cobenfy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cobenfy
Geodon
At A Glance
Oral
Twice daily
Muscarinic agonist/antagonist combination
Oral / IM injection
Twice daily
D2/5HT2 antagonist
Indications
- Schizophrenia
- Schizophrenia
- Bipolar I disorder
Dosing
Schizophrenia Starting dose 50 mg/20 mg orally twice daily for at least 2 days, then 100 mg/20 mg twice daily for at least 5 days; may increase to 125 mg/30 mg twice daily based on tolerability and response (maximum dose); take at least 1 hour before or 2 hours after a meal; do not open capsules. Geriatric patients: start at 50 mg/20 mg twice daily, maximum 100 mg/20 mg twice daily.
Schizophrenia Initiate at 20 mg twice daily with food; may adjust up to 80 mg twice daily at intervals of not less than 2 days.
Schizophrenia (acute agitation, IM) 10-20 mg IM as needed up to 40 mg/day; 10 mg may be given every 2 hours, 20 mg every 4 hours; limit to 3 consecutive days, then transition to oral.
Bipolar I disorder (acute manic/mixed episodes) Initiate at 40 mg twice daily with food; increase to 60 or 80 mg twice daily on day 2; subsequent doses adjusted within 40-80 mg twice daily range based on tolerability and efficacy.
Bipolar I disorder (maintenance, adjunct to lithium or valproate) Continue at the same dose on which the patient was initially stabilized, within the range of 40-80 mg twice daily with food.
Contraindications
- Urinary retention
- Moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment
- Gastric retention
- History of hypersensitivity to COBENFY or trospium chloride
- Untreated narrow-angle glaucoma
- Known history of QT prolongation, including congenital long QT syndrome
- Recent acute myocardial infarction
- Uncompensated heart failure
- Concomitant use with drugs that prolong the QT interval (e.g., dofetilide, sotalol, quinidine, Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol, tacrolimus)
- Known hypersensitivity to ziprasidone or any excipient
- Concomitant use of MAOIs, or use within 14 days of stopping an MAOI
Adverse Reactions
Most common (>=5%) Nausea, dyspepsia, constipation, vomiting, hypertension, abdominal pain, diarrhea, tachycardia, dizziness, gastroesophageal reflux disease
Serious Urinary retention, liver enzyme elevations, increases in heart rate, angioedema
Postmarketing Chest pain, hypertensive crisis, palpitations, supraventricular tachycardia, syncope, gastritis, rash, rhabdomyolysis, confusion, delirium, hallucinations, somnolence, vision abnormal, angioedema, anaphylactic reaction, Stevens-Johnson syndrome (reported with trospium chloride component)
Most common (>=5%) Somnolence, extrapyramidal symptoms, akathisia, dizziness, nausea, constipation, respiratory tract infection, headache, asthenia, abnormal vision
Serious QT prolongation, neuroleptic malignant syndrome, serotonin syndrome, tardive dyskinesia, DRESS, leukopenia, neutropenia, agranulocytosis, seizures
Postmarketing Torsade de pointes, facial droop, galactorrhea, priapism, somnambulism, angioedema, urinary incontinence, postural hypotension, syncope
Pharmacology
Xanomeline is a muscarinic agonist with preferential activity at M1 and M4 receptors in the central nervous system, where its efficacy in schizophrenia is thought to arise; trospium chloride is a peripheral muscarinic antagonist included to reduce cholinergic adverse effects.
Ziprasidone is a dopamine D2/D3 and serotonin 5HT2A/5HT2C antagonist with agonist activity at 5HT1A receptors and inhibition of synaptic reuptake of serotonin and norepinephrine; its antipsychotic and antimanic effects are thought to be mediated through combined D2 and 5HT2 antagonism.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cobenfy
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (8/12) · Qty limit (11/12)
Geodon
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (6/12) · Qty limit (0/12)
UnitedHealthcare
Cobenfy
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (2/8)
Geodon
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Cobenfy
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Geodon
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Cobenfy Copay Assistance ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Geodon.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CobenfyView full Cobenfy profile
GeodonView full Geodon profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.